Details for Patent: 10,357,567

Which drugs does patent 10,357,567 protect, and when does it expire?

Patent 10,357,567 protects LEVULAN and is included in one NDA.

This patent has eleven patent family members in three countries.

Summary for Patent: 10,357,567

Title:	Methods for photodynamic therapy
Abstract:	A method of enhancing penetration of a topical composition of 5-aminolevulinic acid (ALA) into tissue for photodynamic therapy includes topically applying ALA to a treatment area to be treated with photodynamic therapy. The method further includes, after the ALA is applied to the treatment area, covering the treatment area with a low density polyethylene barrier. The treatment area is covered with the low density polyethylene barrier prior to light treatment to minimize transepidermal water loss from the treatment area.
Inventor(s):	Lundahl; Scott (Lexington, MA), Guttadauro; Michael (Carlisle, MA)
Assignee:	DUSA Pharmaceuticals, Inc. (Wilmington, MA)
Application Number:	15/869,164
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,357,567
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,357,567

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Dusa	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes						TREATMENT OF ACTINIC KERATOSES OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY

International Family Members for US Patent 10,357,567

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019200152
Australia	2020103365
Australia	2020267186
Australia	2021102111
Australia	2021107564